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Breakdown of the blood-brain barrier (BBB) and increased immune cell trafficking into
the central nervous system (CNS) are hallmarks of the pathogenesis of multiple sclerosis
(MS). Platelet endothelial cell adhesion molecule-1 (PECAM-1; CD31) is expressed on
cells of the vascular compartment and regulates vascular integrity and immune cell
trafficking. Involvement of PECAM-1 in MS pathogenesis has been suggested by the
detection of increased levels of soluble PECAM-1 (sPECAM-1) in the serum and CSF
of MS patients. Here, we report profound upregulation of cell-bound PECAM-1 in
initial (pre-phagocytic) white matter as well as active cortical gray matter MS lesions.
Using a human in vitro BBB model we observed that PECAM-1 is not essential
for the transmigration of human CD4+ T-cell subsets (Th1, Th1∗, Th2, and Th17)
across the BBB. Employing an additional in vitro BBB model based on primary mouse
brain microvascular endothelial cells (pMBMECs) we show that the lack of endothelial
PECAM-1 impairs BBB properties as shown by reduced transendothelial electrical
resistance (TEER) and increases permeability for small molecular tracers. Investigating
T-cell migration across the BBB under physiological flow by in vitro live cell imaging
revealed that absence of PECAM-1 in pMBMECs did not influence arrest, polarization,
and crawling of effector/memory CD4+ T cells on the pMBMECs. Absence of endothelial
PECAM-1 also did not affect the number of T cells able to cross the pMBMECmonolayer
under flow, but surprisingly favored transcellular over paracellular T-cell diapedesis.
Taken together, our data demonstrate that PECAM-1 is critically involved in regulating
BBB permeability and although not required for T-cell diapedesis itself, its presence or
absence influences the cellular route of T-cell diapedesis across the BBB. Upregulated
expression of cell-bound PECAM-1 in human MS lesions may thus reflect vascular repair
mechanisms aiming to restore BBB integrity and paracellular T-cell migration across the
BBB as it occurs during CNS immune surveillance.
Keywords: blood-brain barrier, endothelial junctions, PECAM-1, T-cell diapedesis, vascular permeability, multiple
sclerosis
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INTRODUCTION
Multiple sclerosis (MS) is a chronic demyelinating disorder
of the central nervous system (CNS), which is characterized
by a disease course-dependent degree of inflammation, axonal
damage, oligodendrocyte death, and astrocytic scar formation
affecting the white and gray matter of brain and spinal cord (1).
Loss of blood-brain barrier (BBB) integrity is an early hallmark
of acute and relapsing-remitting MS and can be visualized by the
leakage of the magnetic resonance imaging (MRI) contrast agent
gadolinium into the CNS parenchyma (2). T cells were shown
to substantially contribute to MS pathogenesis (3, 4). Therapies
targeting T-cell trafficking into the CNS by e.g., inhibiting T-cell
egress from lymph nodes into the blood by fingolimod treatment
or by restricting T-cell adhesion to the BBB endothelium by the
humanized anti-α4 integrin antibody natalizumab, greatly reduce
relapse rates in MS (5).
The BBB maintains CNS homeostasis, which is a prerequisite
for the proper functioning of neurons and glial cells by
shielding the CNS from an uncontrolled entry of blood-borne
molecules. The highly specialized endothelial cells of the CNS
microvasculature forming the BBB are part of the neurovascular
unit, in which the interaction of pericytes, astrocytes as well
as acellular extracellular matrix components ensure proper BBB
function (6). Barrier characteristics of the highly specialized
BBB endothelial cells are established by their low pinocytotic
activity as well as their unique cell-to-cell junctions (6). In
addition to regular adherens junctions established by the VE-
cadherin/catenin complex, BBB endothelial cells are connected
by complex and molecularly unique tight junctions established
by members of the claudin and junctional adhesion molecule
(JAM) families and the intracellular scaffolding proteins ZO-1,
ZO-2, and ZO-3 [reviewed in (7)]. Outside of these organized
junctional complexes, the BBB cell-to-cell contacts harbor
additional transmembrane proteins such as platelet endothelial
cell adhesion molecule-1 (PECAM-1) and CD99, which have
been suggested to contribute to the regulation of vascular
integrity and immune cell extravasation [reviewed in (7)].
Immune cell trafficking into the CNS is strictly controlled
by the BBB and is a multistep process [reviewed in (8)]. It is
initiated by a transient contact of the circulating immune cell
with the BBB endothelium followed by rolling of the immune
cell with reduced velocity along the vascular wall leading to its
arrest, polarization, and subsequent crawling to sites permissive
for diapedesis. Transmigration of immune cells across the
vascular wall can either occur through the endothelial cell-cell
junctions via the paracellular pathway mediated by the well-
orchestrated rapid remodeling and sequential opening/closing
of the interendothelial junctions in a zipper-like fashion (9), or
through the endothelial cell body via a transcellular route by the
formation a transcellular pore (10). It has long been thought
that the unique cell-to-cell junctions of the BBB endothelium
prohibit paracellular immune cell diapedesis across the BBB
[reviewed in (11)]. However, recent evidence has shown that
in the course of immune surveillance and thus in the absence
of neuroinflammation, T cells preferentially cross the BBB via
the paracellular route while transcellular T-cell penetration of
the BBB is rather observed during active neuroinflammation as
observed in experimental autoimmune encephalomyelitis (EAE),
the animal model for MS (12, 13).
PECAM-1 is a type 1 transmembrane glycoprotein of the
immunoglobulin (Ig) superfamily of cell adhesion molecules
(14, 15). It contains six extracellular Ig-like domains and two
cytoplasmic immune receptor tyrosine inhibitory motifs (16).
PECAM-1 is expressed on platelets, endothelial cells, neutrophils,
monocytes, and selected lymphocyte subsets (17–20). It is highly
enriched at interendothelial junctions of vascular endothelial
cells (17) and mediates neutrophil diapedesis across the vascular
wall (21–23) as well as vascular integrity (24, 25). Moreover, it
has been shown that PECAM-1 acts as vascular mechanosensor
(26–28) and plays an important role in angiogenesis and vascular
remodeling (29–32).
Involvement of PECAM-1 in MS pathogenesis is supported
by our previous observation that PECAM-1−/− C57BL/6 mice
display aggravated clinical EAE due to impaired BBB integrity
and accelerated immune cell infiltration into the CNS (24). In
patients with relapsing-remitting MS, elevated serum levels of
soluble PECAM-1 (33, 34), increased numbers of circulating
PECAM-1-positive microparticles (35) as well as increased
expression of PECAM-1 on circulating leukocytes (36) have
been observed. Interestingly, interferon-β, a disease-modifying
therapy for MS (37), increases vascular PECAM-1 expression
(38) suggesting that an elevated expression of PECAM-1 might
contribute to amelioration of MS.
Here, we found a profound upregulation of PECAM-1
transcripts in initial (pre-phagocytic) white matter as well
as active cortical gray matter MS lesions and localized the
upregulated PECAM-1 protein to the vascular endothelium. We
show that endothelial PECAM-1 contributes to the regulation of
BBB integrity. Furthermore, while not required for the rate of T-
cell diapedesis across the BBB, endothelial PECAM-1 was found
to regulate the route of T-cell diapedesis, since its absence shifted
T-cell migration across the BBB to the transcellular pathway. Our
data suggest that increased vascular expression of PECAM-1 in
MSmay contribute to BBB stabilization and restoration of tightly
controlled T-cell trafficking into the CNS.
MATERIALS AND METHODS
RNA Isolation From FFPE Tissue and
Whole-Genome Microarrays
Studies on human autopsy material were performed according
to the Austrian legislation and were approved by the ethics
committee of the Medical University of Vienna (No 535/2004).
For the determination of PECAM-1 transcription levels, pre-
existing microarray data sets, which have already been published
before with regard to other research questions (39–44), were
once more re-evaluated. As described, well-characterized white
and gray matter lesions from archival formalin-fixed paraffin-
embedded (FFPE) autopsy tissue fromMS patients (cases of acute
MS for the dissection of white matter lesions; cases of secondary
progressive MS for the dissection of gray matter lesions) as
well as respective control tissue from controls cases without
Frontiers in Immunology | www.frontiersin.org 2 April 2019 | Volume 10 | Article 711
Wimmer et al. PECAM-1 in Neuroinflammation
confounding neuropathology were dissected frommultiple tissue
sections. Overall, PECAM-1 expression in the periplaque white
matter (PPWM) from 3MS patients, 4 initial (pre-phagocytic)
lesions (45, 46) from 3MS patients and 5 active demyelinating
lesions (47) from 4MS patients was compared to transcript
levels in normal white matter (NWM) from 4 controls. Likewise,
active cortical gray matter lesions from 3MS patients and
normal cortical gray matter from 3 control cases were analyzed.
Details on the study cohort, RNA isolation, quality control,
microarray hybridization and data normalization have already
been extensively described (39, 40).
Immunohistochemistry
In total, we examined archival autopsy tissue of 20MS patients
including 6 cases of acute MS (death within 1 year after disease
onset), 8 with secondary progressive MS and 6 with primary
progressive MS. Additionally, 13 control cases without any
confounding neuropathology were included. Characterization
and classification of perilesional and lesional areas into different
categories was done according to published criteria (48). Shortly
described, the periplaque white matter is characterized by a
loosened tissue structure due to edema and sparse perivascular
inflammatory infiltrates andmicroglia activation can be detected,
while myelin and oligodendrocytes are still intact. In initial (pre-
phagocytic) lesions, myelin is still mostly preserved. Microglia
activation, oligodendrocyte apoptosis and tissue edema are
prominent, while tissue infiltration by peripheral macrophages
is sparse. In active demyelinating white matter lesions, myelin
is lost and myelin fragments are ingested by phagocytes,
which numerously infiltrate these lesional areas. Likewise, tissue
edema and dissolution of tissue structures is far advanced.
Representative pictures for periplaque white matter, initial lesion
and active demyelinating lesion were taken from an acute MS
patients (34 years old; female; 4 months of disease duration);
for active gray matter lesions from a secondary progressive MS
case (42 years old; male; 216 months of disease duration); for
normal white and gray matter areas from a 36 year-old female
person. For antibody double-labeling of human FFPE tissue, 3–
5µm sections were routinely dewaxed in xylene and rehydrated
in a descending ethanol series. Endogenous peroxidase activity
was blocked by incubation of the slides in methanol/0.2% H2O2
for 30min. For antigen retrieval, slides were steamed for 1 h
in 10mM Tris/1mM EDTA buffer (pH 9.0). Thereafter, tissue
sections were washed in Tris-buffered saline (TBS). Non-specific
background binding was blocked with 10% fetal calf serum
(FCS)/Dako buffer (Dako) for 20min. Primary anti-PECAM-1
antibody (Neomarkers; diluted 1:200 in 10% FCS/Dako buffer)
was applied and incubated over night at 4◦C. Tissue sections
were washed in TBS and incubated with biotinylated anti-
mouse antibody (Jackson ImmunoResearch; diluted 1:500 in
10% FCS/Dako buffer) for 1 h at room temperature. After
washing in TBS, PECAM-1 antibody labeling was developed
with 3,3′-diaminobenzidine tetrahydrochloride hydrate (DAB).
Subsequently, primary anti-PLP antibody (formerly provided by
Prof. Paul Morgan, Cardiff University; diluted 1:250 in 10%
FCS/Dako buffer) was applied and incubated over night at 4◦C.
Tissue sections were washed in TBS and incubated with an
alkaline phosphatase-conjugated anti-rabbit antibody (Jackson
ImmunoResearch; diluted 1:200 in 10% FCS/Dako buffer) for 1 h
at room temperature. PLP staining was developed using the Fast
Blue system as previously described (49). Tissue sections were
mounted with geltol.
Human T Cells
Human CD4+CD45RO+ T cells were sorted from the peripheral
blood of healthy donors according to their specific expression
pattern of chemokine receptors (CXCR3+ CCR4− CCR6− for
Th1; CXCR3+ CCR4− CCR6+ for Th1∗; CXCR3− CCR4+
CCR6− for Th2; CXCR3− CCR4+ CCR6+ for Th17) exactly
as previously described (50, 51). T cells were cultured in the
presence of interleukin-2 (IL-2; 500 U/ml) for a total of 20
days and were stored at −80◦C. For each experimental run,
T cells were thawed and dead cells were removed by a Ficoll
gradient centrifugation (780 × g, 20min, 20◦C) and T cells
were resuspended in migration assay medium (DMEM without
phenol red/25mMHEPES/5% fetal bovine serum (FBS)/4mML-
glutamine). T cells were labeled with 1µM CMFDA cell tracker
(Life Technologies, ThermoFisher) for 30min at 37◦C.
Human in vitro BBB Model and
Transmigration Assay
The study protocol was approved by The French Ministry of
Higher Education and Research (CODE-COHNumber DC2011-
1321) and written informed consent was obtained from the
infants’ parents prior to the collection of the infants’ umbilical
cord blood. The CD34+ cell-derived human in vitro BBB model
was prepared exactly as described before (52, 53). Shortly
described, brain-like endothelial cells (BLECs) were cultured on
filter inserts (PC membrane, pore size 3.0µm; Costar, 3402) for 7
days. Subsequently, they were co-cultured with bovine pericytes
(52, 53) for 6 days to induce BBB-like characteristics. For the
transmigration assay, BLECs were stimulated with both TNF-
α (1 ng/ml; R&D Systems, 210-TA) and IFN-γ (20 IU/ml; R&D
Systems, 285-IF) in the serum-containing complete Endothelial
Cell Medium (ScienCell) for 16 h. Thereafter, BLECs were treated
with either anti-human PECAM-1 (20µg/ml; clone hec7), or
anti-human CD99 (20µg/ml; clone hec2) or anti-human ICAM-
1 [10µg/ml; clone BBIG-I1 (11C81), R&D Systems] antibodies,
or the appropriate isotype controls for 30min at 37◦C. After
incubation 1.5 × 105 of the labeled T helper cells (either Th1,
Th1∗, Th2, or Th17 cells) were added to the upper chamber. T-
cell transmigration was allowed for 8 h at 37◦C in the presence
of either blocking antibody or isotype control. The absolute
numbers of transmigrated cells were counted using a CASY cell
counter (OMNI Life Science).
Mice
All mice were bred and housed in individually ventilated cages
under specific pathogen-free conditions at the University of
Bern. Experiments were carried out in compliance with the
Swiss legislation on the protection of animals and the veterinary
office of the Kanton of Bern (permission numbers: BE 66/12
and BE 72/15). All animals were from the C57BL/6 background.
PECAM-1−/− C57BL/6 mice were descendants from previously
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described PECAM-1 knock-out mice (54). VE-CadGFP knock-
in mice (55) were kindly provided by D. Vestweber (Münster,
Germany). PECAM-1−/− VE-CadGFP mice were obtained
by cross-breeding. Wild-type (WT) littermates were used
as controls.
Isolation of Primary Mouse Brain
Microvasculature Endothelial
Cells (pMBMECs)
Primary mouse brain microvasculature endothelial cells
(pMBMECs) were isolated from 1 to 2 months old male and
female mice and cultured exactly as described (56, 57). Capillaries
from two brains allowed for seeding either 6 cloning rings (6mm
diameter), 4 filter inserts, 4 wells of a 16-well chamber slide,
or 1 well of a 24-well plate. If isolated microvessels were not
immediately plated, they were frozen in 100 µl freezing medium
(30% fetal bovine serum, 10% DMSO, and 60% DMEM) per
brain. After thawing, microvessels were seeded double as
concentrated as freshly isolated ones.
Mouse T Cells
Proteolipid protein (PLP)-specific CD4+ effector T cells from
lines SJL.PLP4 and SJP.PLP7 were used 2–3 days after the 3rd,
4th, 5th, or 7th restimulation with their specific PLP peptide
aa139-151 (58). Briefly, for the restimulation of established
cell lines, spleens of SJL wild-type mice were collected,
homogenized in Hank’s balanced salt solution (HBSS)/25mM
HEPES buffer/5% calf serum using a sterile WheatonTM
homogenizer (Loose pestle), filtered (100µm mesh size)
and irradiated with 40Gy (Gammacell 3000 Elan, Nordion
International Inc.). Afterwards, red blood cells were lysed.
Generally, 1.5–2 × 106 resting T cells were restimulated with 3–
4 × 106 splenocytes and 10µg/ml PLP peptide in 60mm dishes
filled with 5ml restimulation medium (RPMI, 10% FBS, 4mM
L-glutamine, 100 U/ml penicillin, 100µg/ml streptomycin, 1%
non-essential amino acids, 1mM sodium pyruvate, 50µM β-
mercaptoethanol). After 48 h incubation (37◦C and 7% CO2),
1ml TCGF medium (restimulation medium supplemented with
IL-2-containing cell supernatant) was added to each dish. After
16 h, activated T-cell blasts were purified on a NycoPrepTM 1.077
gradient (Progen Biotechnik GmbH) and seeded at a density
of 2.5–3 × 106 cells per 100mm dish in TCGF medium. The
antigen-specific activated T cells were either used for experiments
or cultured for 9–11 days and subsequently subjected to another
round of restimulation.
In vitro Live Cell Imaging Under
Flow Conditions
WT and PECAM-1−/− pMBMECs were seeded in cloning
rings placed on matrigel-coated Ibidi µ-dishes. Six to seven
days after isolation, pMBMEC monolayers were stimulated with
20 ng/ml IL-1β (PeproTech) in the presence of serum and
flow movies were recorded within 16–24 h post stimulation.
Generally, in vitro live cell imaging was done as described
(59). Briefly, a custom-made flow chamber was mounted on an
Ibidi dish, placed on a heated stage of an inverted microscope
(AxioObserver Z1 equipped with a monochrome CCD camera;
both Zeiss) and connected to an automated syringe pump
(Harvard Apparatus). Using low shear stress (0.1 dyn/cm2),
T cells were perfused over the pMBMEC monolayer and
allowed to accumulate for 5min. Thereafter, medium flow was
increased to physiological shear stress (1.5 dyn/cm2). To study
the interaction of T cells with pMBMECs, 1 × 106 T cells/ml
(DMEM/2% L-glutamine/25mM HEPES/5% calf serum) were
perfused over the endothelial monolayer and phase-contrast
images were acquired every 5 s for a total of 20min using a
20 × objective. For the analysis of time-lapse videos, ImageJ
software (National Institutes of Health) was used. First, the
number of arrested T cells was counted one frame after increasing
the flow rate to physiological shear. Then, the behavior of each
arrested T cell was determined and classified into 4 categories
as follows: T cells either detached during the observation period
(“detachment”), remained situated at the same position mostly
probing their surrounding via their protrusions (“probing”),
continuously crawled on the endothelial surface (“crawling”), or
migrated across the pMBMEC monolayer (with or without prior
crawling; “diapedesis”). If T cells exhibited any moving behavior,
defined as cell displacement of more than one cell diameter, the
crawling path was tracked using the Manual Tracking plugin
of ImageJ (https://imagej.nih.gov/ij/plugins/track/track.html).
Crawling speed, crawling distance and crawling directionality
of each T cell were calculated using the Chemotaxis and
Migration Tool plugin (https://ibidi.com/chemotaxis-analysis/
171-chemotaxis-and-migration-tool.html). To determine the
diapedesis route, 2 × 106 T cells/ml (DMEM without
phenol red/2% L-glutamine/25mM HEPES/5% calf serum) were
perfused over VE-CadGFP pMBMECs (WT as well as PECAM-
1−/−) and differential interference contrast (DIC) pictures as well
as pictures with a GFP filter were taken every 30 s for a total
of 30min with a 63 × objective. T-cell diapedesis interrupting
the continuous junctional VE-CadGFP signal was categorized as
paracellular diapedesis. Diapedesis, which did not interrupt the
continuous junctional GFP signals, was classified as transcellular.
Each video represents an independent experiment carried out
with separate pMBMECs and T-cell aliquots.
Immunofluorescence Stainings
WT and PECAM-1−/− pMBMECs were seeded on matrigel-
coated 16-well glass NuncTM Lab-TekTM chamber slides (Thermo
Fisher Scientific) or removable 12-well chamber glass slides
(Ibidi). If required, pMBMECs were stimulated at the 6th day
after isolation with IL-1β (20 ng/ml) in the presence of serum
for 16 h. Seven days after isolation, cells were fixed with 100
µl 1% PFA for 10min or, in the case of occludin and VE-
cadherin, in−20◦C-cold methanol for 30 s. Thereafter, cells were
permeabilized in blocking buffer (5% skimmed milk, 0.3% Triton
X-100, 0.04% NaN3 in TBS) for 20min. Hybridoma supernatants
[rat-anti-mouse: PECAM-1 (Mec13.3), VE-cadherin (11D4),
ICAM-1 (25ZC7), JAM-A (BV12); rat-anti-human CD44 (9B5)
used as isotype control] were applied without prior dilution. ZO-
1 antibody (rabbit polyclonal; 1:100; Thermo Fisher Scientific),
rabbit polyclonal occludin antibody (1.25µg/ml Thermo Fisher
Scientific), rabbit polyclonal claudin-5 antibody (1.25µg/ml,
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Thermo Fisher Scientific) and rabbit IgG (R&D Systems) were
diluted in blocking solution. Primary antibodies were incubated
for 30min at room temperature. After washing of wells with PBS,
secondary antibodies (goat-anti-rat Alexa488, Thermo Fisher
Scientific; goat-anti-rabbit Cy3, Jackson ImmunoResearch) were
applied together with DAPI (0.5µg/ml) for 30min at room
temperature and slides were mounted in Mowiol.
Western Blot
WT and PECAM-1−/− pMBMECs were seeded in matrigel-
coated 24-well plates. Six days after isolation, pMBMEC
monolayers were stimulated or not with IL-1β (20 ng/ml) for
16 h. Cells were washed and lysed in 70 µl ice-cold RIPA
buffer [50mM Tris, 150mM NaCl, 0.1% sodium deoxycholate,
0.1% sodium dodecyl sulfate, 1% NP-40, protease inhibitors
(Roche), pH 7.5]. Protein quantity was determined using the
PierceTM BCA Protein Assay Kit according to manufacturer’s
instructions. Hundred microgram of each sample were mixed
with 2X SDS sample buffer, heated to 95◦C for 5min and
separated by SDS-PAGE (10% resolving gel; 90V for 30min and
120V for 1.5 h). Proteins were transferred to a nitrocellulose
membrane (semi-dry blotting at 15V for 15min), which
was blocked for 1 h in 5% skimmed milk powder in TBST
buffer. Polyclonal rabbit anti-ICAM-1 raised against mouse
immune globulin domains 1 and 2 (custom made, Eurogentec,
Seraing, Belgium) (53) was diluted 1:1000 in 5% skimmed milk
powder/TBST and incubated overnight at 4◦C. After washing
with TBST, GAPDH antibody (rabbit monoclonal; Cell Signaling
Technology; 1:1000) was applied for 1 h at room temperature.
Both antibodies were visualized simultaneously with IRDye680-
conjugated goat-anti-rabbit IgG (Li-Cor Biosciences) incubated
for 1 h at room temperature. Signals were visualized using an
Odyssey reader (Li-Cor Biosciences) and quantified via Image
Studio Lite v4.0 (Li-Cor Biosciences). Background subtraction
was done automatically. Protein size was referenced to a pre-
stained protein ladder (Thermo Fisher Scientific, 26635). For
each sample, ICAM-1 signals were normalized to GAPDH.
Furthermore, IL-1β-stimulated WT and PECAM-1−/− as well
as untreated PECAM-1−/− samples were further related to
untreated WT samples. Reported results derive from four
independent experiments.
Impedance Spectroscopy
WT and PECAM-1−/− pMBMECs were seeded on laminin-
and matrigel-coated filter inserts (transparent PET membrane,
pore size 0.4µm; Greiner Bio-one, 662641). On the following
2 days, cells were thoroughly washed during medium change.
Then, 48 h after cell isolation, filter inserts were transferred to
the cellZscope R© (nanoAnalytics) for impedance spectroscopy
allowing to monitor the transendothelial electrical resistance
(TEER; one measurement per hour) over several days. After
a stable TEER plateau had formed, pMBMECs were either
treated with IL-1β (final concentration: 20 ng/ml) or the identical
volume of PBS. The experiment was terminated 2 days later.
Via the cellZscope R© software, hourly TEER values for each filter
insert were exported to Microsoft Excel. To determine TEER
differences between WT and PECAM-1−/− pMBMECs during
the stable plateau phase, the maximal resistance values 80–
90 h after initiating cellZscope measurements were analyzed and
reported in relation to WT cells. In order to analyze the effect of
IL-1β stimulation, the ratio between the TEER value 16 h after
cytokine/PBS treatment and the TEER value immediately before
stimulation was calculated for each filter insert. Thereafter, ratios
of IL-1b-treated WT and PECAM-1−/− samples were related to
ratios of the respective controls.
Permeability Assays
WT and PECAM-1−/− pMBMECs were seeded on laminin-
and matrigel-coated filter inserts (translucent polycarbonate
membrane, pore size 0.4µm; Corning Costar). Six days after
isolation, pMBMEC monolayers were stimulated with IL-1β
(20 ng/ml)- or PBS-conditioned medium for 16 h. Permeability
assays and permeability coefficient (Pe) calculations were
performed as described previously (56). Shortly described, 50µM
Lucifer Yellow CH dilithium salt (Sigma-Aldrich) and 10µg/ml
Alexa–Fluor-680-conjugated 3 kDa dextran (Molecular Probes)
were loaded into the upper compartment of the filter inserts.
For the clearance experiments, the amount of fluorescent tracer
diffusing through the endothelial monolayer was determined
every 10min for a total of 40min and quantified using an Infinite
M1000 (Tecan) and Odyssey (Li-Cor Biosciences) reader for
Lucifer yellow and dextran, respectively. Permeability coefficients
were calculated for each insert according to Coisne et al.
(56). Assays were carried out in HBSS without phenol red
supplemented with 5% fetal bovine serum and 25mM HEPES.
Each experiment was done in technical triplicates. Analyses
combine four independent experiments.
Determination of Monolayer Integrity
After termination of permeability assays and TEER
measurements, filter inserts were fixed in 3.7% formaldehyde
for 10min and incubated for 20min in staining solution (PBS,
1% BSA, 0.1% Triton X-100, 12.5µg/ml rhodamine phalloidin,
0.5µg/ml DAPI). Filters were cut out and mounted. Integrity
of pMBMEC monolayers was determined at the AxioObserver
Z1 (equipped with Cy3 and Dapi filters) using ZEN 2012 blue
edition software (both Carl Zeiss).
Statistics
For statistical analysis, GraphPad Prism v.6.01 was used.
Generally, reported statistics result from unpaired, two-tailed
Student’s t-tests, one-way ANOVA with either Dunnett’s or
Sidak’s multiple comparisons test or from Pearson’s qui-square
test. Microarray data were analyzed by non-parametric Kruskal-
Wallis and Mann-Whitney U-tests. Asterisks indicate significant
differences (∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.001).
RESULTS
PECAM-1 Expression Is Increased in Initial
White Matter and Active Cortical
MS Lesions
In previous studies, we have performed gene expression analyses
comparing active cortical MS lesions to cortical tissue of
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other inflammatory and neurodegenerative brain diseases as
well as different stages in white matter lesion development
to normal white matter of controls. We identified potential
molecular pathways of tissue injury and reported on the
differential expression of oxidative stress-, microglia-, and iron-
related genes (39–44). In addition these microarray data sets
revealed a pronounced upregulation of PECAM-1 transcripts
in MS lesions (Figures 1A,B). In comparison to normal white
matter (NWM) from non-neurological controls, PECAM-1
expression was more than 5-fold increased in initial (pre-
phagocytic) white matter MS lesions (IniL), while it was only
slightly upregulated in the periplaque white matter (PPWM)
and unchanged in active demyelinating lesions (ActL). In
active cortical gray matter lesions (GML), we noticed a
pronounced expression of PECAM-1 in comparison to cortical
tissue from control patients (NGM). Immunohistochemical
labeling confirmed the differential expression of PECAM-1
during MS lesion maturation on vascular endothelial cells.
Endothelial PECAM-1 staining was most pronounced in initial
(pre-phagocytic) MS lesions (Figure 1G), while it was less
strong in the PPWM (Figure 1F), active demyelinating lesions
(Figure 1H) or the NWM of controls (Figure 1E). Likewise,
PECAM-1 expression by endothelial cells was higher in cortical
gray matter MS lesions (Figure 1D) compared to cortical
tissue of control cases without confounding neuropathology
(Figure 1C). Based on our results it is tempting to speculate that
dysregulated endothelial PECAM-1 expression may influence
MS pathogenesis.
Endothelial PECAM-1 Is Not Essential for
T-Cell Diapedesis Across a Static Human
in vitro BBB Model
We first asked if a dysregulated vascular PECAM-1 expression
would influence T-cell trafficking into the CNS. To this end,
we tested if PECAM-1 is involved in the migration of human
effector/memory CD4+ T cells across a human in vitro model
of the BBB (52, 53). Using static conditions and 4 subsets of
human T helper cells [classical Th1, Th1∗,Th2, Th17 (60)] we
found that functional antibody-mediated blockade of endothelial
PECAM-1 does not interfere with the transmigration rate of
the different T-cell subsets of human effector/memory CD4+ T
cells across our TNF-α-/IFN-γ-stimulated human BBB model
(Figure 2), although a small percentage of Th1 and Th2
cells expressed PECAM-1 allowing for homophilic interactions
(Supplementary Figure 1). At the same time, addition of anti-
humanCD99 or anti-human ICAM-1 blocking antibodies greatly
reduced the rate of T-cell diapedesis and confirmed the validity of
our experimental setup. Thus, PECAM-1 is not required for the
diapedesis of human effector/memory CD4+ T cells across our
human in vitro BBB model.
PECAM-1−/− pMBMECs Maintain an Intact
Junctional Architecture
Next we asked if dysregulated endothelial expression of PECAM-
1 may also lead to BBB dysfunction. To test this hypothesis, we
employed our well-established mouse in vitromodel for the BBB
FIGURE 1 | Gene and protein expression of PECAM-1 is pronounced in initial white matter MS lesions and active cortical MS lesions. (A) Representative schematic
overview of the different MS lesions included in the microarray analyses. The separately microdissected zones are encircled by differently colored lines: yellow, active
demyelinating lesion; orange, initial (pre-phagocytic) lesion; pink, periplaque white matter; brown, active cortical gray matter lesion. White matter is depicted in blue;
the cortical ribbon is depicted in rose. (B) Gene expression analysis in microdissected MS brain lesions. PECAM-1 expression in affected white matter areas (n = 4
patients) was compared to normal white matter of healthy controls (n = 4 subjects); PECAM-1 expression in active cortical gray matter MS lesions (n = 3 patients)
was compared to cortical areas isolated from healthy controls (n = 3 subjects). Non-parametric analyses did not reach any significance levels (white matter: H(3) =
1.888, p = 0.6284; gray matter: U = 0.000, z = −1.964, p = 0.100, r = −0.802). PPWM, periplaque white matter; IniL, initial (pre-phagocytic) lesions; ActL, active
demyelinating lesions; NWM, normal white matter; GML: gray matter lesion; NGM: normal gray matter (C–H) Immunohistochemical double-labeling for PECAM-1
(brown) and the myelin component proteolipid protein (PLP; blue) of normal gray matter of control (C), active cortical gray matter MS lesion (D), normal white matter of
control (E), periplaque white matter (F), initial (pre-active) MS lesions (G) and active MS lesions (H). Representative pictures are shown. Scale bars, 100µm.
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FIGURE 2 | PECAM-1 is not required for the diapedesis of human
effector/memory CD4+ T cells across BLECs. Diapedesis of human CD4+
T-cell subsets (Th1, Th1*, Th2, and Th17) across the TNF-α-(1 ng/ml) +
IFN-γ-stimulated (20 IU/ml) human in vitro BBB model (BLECs) is shown. Prior
to addition of T cells, BLECs were pre-treated with anti-human PECAM-1,
anti-human CD99 or anti-human ICAM-1 blocking antibodies or the adequate
isotype control antibodies. T cells were allowed to migrate for 8 h across the
BLEC monolayers. Transmigration rates are expressed relative to isotype
control-treated filter inserts (100%). Data are derived from three independent
experiments each performed in triplicates, except for ICAM-1 blocking
conditions, which were done in two independent experiments each performed
in triplicates. T cells were derived from 3 different healthy donors. Dots
represent individual data points; error bar ± SEM. Reported statistics result
from one-way ANOVAs with Dunnett’s multiple comparisons tests. **p < 0.01;
***p < 0.001; ****p < 0.0001.
(56), in which primary mouse brain microvascular endothelial
cells (pMBMECs) form a tight and polarized cellular barrier
(61). First, we generated pMBMEC cultures fromwild-type (WT)
and PECAM-1−/− C57BL/6 mice and further investigated if lack
of PECAM-1 affects the basic barrier architecture of pMBMEC
monolayers. Both WT and PECAM-1−/− pMBMECs formed
confluent monolayers. Junctional immunostaining for PECAM-
1 was prominent in WT, but absent in PECAM-1−/− pMBMECs
(Figure 3A). WT and PECAM-1−/− pMBMECs displayed
indistinguishable junctional localization of the transmembrane
adherens junction molecule VE-cadherin (Figure 3B) as well the
transmembrane tight junction proteins claudin-5, JAM-A and
occludin (Figure 3C). Also, the junctional localization of the
intracellular scaffolding protein zonula occludens-1 (ZO-1) was
unaffected by the lack of PECAM-1 (Figure 3D). Isotype control
stainings did not show differences between WT and PECAM-
1−/− pMBMECs (Figure 3E). Thus, the overall molecular
architecture of interendothelial junctions was not affected by the
absence of PECAM-1.
Lack of Endothelial PECAM-1 Impairs
Barrier Integrity of pMBMEC Monolayers
As a next step, we investigated barrier characteristics of
pMBMEC monolayers established from WT and PECAM-
1−/− C57BL/6 mice. First, we examined the transendothelial
electrical resistance (TEER) of the pMBMEC monolayers by
impedance spectroscopy starting 48 h after seeding the freshly
isolated brain capillaries. TEER values increased comparably
for both WT and PECAM-1−/− pMBMECs reaching a plateau
with a maximum TEER at day 5 (approximately 72 h after
start of measurements) that subsequently remained constant
for several days (Figure 4A). Lack of endothelial PECAM-
1 did not delay barrier formation of pMBMEC monolayers,
however, the maximum TEER of PECAM-1−/− pMBMECs was
significantly lower compared to WT pMBMECs (Figure 4B).
Next, we asked, whether these already reduced barrier properties
of PECAM-1−/− pMBMECs would be further affected under
inflammatory conditions. We have previously reported that the
pro-inflammatory cytokine IL-1β impairs barrier characteristics
of pMBMEC monolayers (12). In agreement with these
observations, IL-1β stimulation of WT pMBMECs reduced
the TEER of the monolayers when compared to control
treatment (Figure 4C). For PECAM-1−/− pMBMECs, which
displayed already a significantly lower TEER under unstimulated
conditions (Figure 4B), IL-1β treatment further reduced the
TEER to the same degree as observed for WT pMBMECs
(Figure 4D). Thus, IL-1β reduced the TEER across WT and
PECAM-1−/− pMBMEC monolayers in a comparable and thus
PECAM-1-independent manner.
Barrier properties of confluent pMBMEC monolayers were
further investigated by examining their permeability for the
two fluorescent tracers Lucifer yellow (457 Da) and Alexa-
Fluor-680-conjugated 3 kDa dextran. Both tracers diffused
at a significantly higher rate across unstimulated PECAM-
1−/− pMBMEC monolayers when compared to unstimulated
WT pMBMECs (Figures 4E,F). IL-1β treatment was previously
found to elevate the diffusion rates of small molecular tracers
across pMBMECs (12). Interestingly, upon IL-1β stimulation,
PECAM-1−/− pMBMECs did not exhibit a further increase in
permeability for Lucifer Yellow or Alexa-Fluor-680-conjugated
3 kDa dextran, when compared to IL-1β-stimulated WT
pMBMECs (Figures 4E,F). This may be due to the fact that the
barrier function of unstimulated PECAM-1−/− pMBMECs is
already too impaired, thus masking a further increase of tracer
diffusion after stimulation with IL-1β in this experimental setup.
Nevertheless, these observations underscore the involvement
of PECAM-1 in regulating BBB integrity. Taken together,
absence of PECAM-1 significantly impaired barrier properties
of pMBMEC monolayers without visibly affecting the overall
molecular architecture of their adherens and tight junctions.
Absence of Endothelial PECAM-1 Does Not
Affect Arrest and Crawling of
Encephalitogenic T Cells on pMBMECs
We and others have previously shown that increased vascular
permeability does not allow predicting effects on immune
cell trafficking across the vascular border (12, 62). On the
other hand we had previously observed that PECAM-1−/−
C57BL/6 mice develop early onset of EAE due to enhanced
immune cell trafficking into the CNS (24). Therefore, to address
this, we studied the interaction of effector/memory CD4+ T
cells with pMBMEC monolayers under physiological flow by
in vitro live cell imaging (59). The employed encephalitogenic
T cells expressed PECAM-1 allowing for homophilic interaction
with endothelial PECAM-1 (Supplementary Figure 1). The
behavior of those T cells that arrested on the pMBMEC
monolayers under physiological shear forces was classified into
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FIGURE 3 | PECAM-1−/− pMBMECs display an intact junctional architecture. Immunofluorescent stainings of WT and PECAM-1−/− pMBMEC monolayers were
performed for PECAM-1 (A), VE-cadherin (B), claudin-5 (C), JAM-A (C), occludin (C), and ZO-1 (D). Additionally, the fluorescent signal of VE-CadGFP-expressing
pMBMECs is shown (B). Also, stainings for mouse and rabbit isotype controls are presented (E). Cell nuclei were stained with DAPI. Merged grayscale pictures of
nucleic signals and the specific antibody stainings are shown. Scale bars, 50 µm.
4 categories (detachment, probing, crawling, and diapedesis)
as described in the Materials and Methods section. We found
that encephalitogenic CD4+ T cells arrested in comparable
numbers on IL-1β-treated WT and PECAM-1−/− pMBMECs
(Figure 5A). From this pool of arrested cells, a minority
constantly crawled over IL-1β-stimulatedWT and PECAM-1−/−
pMBMEC monolayers during an observation period of 20min,
while the majority underwent diapedesis irrespective of previous
crawling (Figure 5B). A small, comparable percentage of arrested
T cells remained probing on both WT and PECAM-1−/−
pMBMECs, while a negligible, and again comparable, number
of T cells detached from both WT and PECAM-1−/− pMBMEC
monolayers during the observation time. Taken together, absence
of endothelial PECAM-1 did not affect any post-arrest T-cell
behavior on IL-1β-stimulated pMBMEC monolayers under flow
in vitro (Figure 5B).
Interestingly, T cells that eventually crawled on the pMBMEC
monolayers needed significantly more time to start their active
crawling behavior on PECAM-1−/− pMBMECs compared
to WT pMBMECs (Figure 5C). Other T-cell parameters
such as crawling speed, accumulated crawling distance and
Euclidian crawling distance on IL-1β-stimulated pMBMECs
were not influenced by the lack of endothelial PECAM-1
(Figures 5D–F). Also, the time lag between the stop of T-
cell crawling and start of diapedesis across IL-1β-stimulated
pMBMEC monolayers (Figure 5G), the overall duration of T-
cell diapedesis (Figure 5H) as well as the percentages of T
cells, which crawled or stayed stationary prior to diapedesis
(Figure 5I) were not altered between WT and PECAM-
1−/− pMBMECs.
Altogether, we found that the absence of endothelial PECAM-
1 hardly affected common parameters of T-cell interaction with
IL-1β-stimulated pMBMECs. Solely the time span, which T cells
needed to start post-arrest crawling, was significantly influenced
by the lack of endothelial PECAM-1.
Lack of Endothelial PECAM-1 Favors
Transcellular Over Paracellular T-Cell
Diapedesis Across pMBMEC Monolayers
Under Physiological Flow
Considering the predominant junctional localization of
endothelial PECAM-1, we finally asked if the lack of endothelial
PECAM-1 affects the cellular pathway of T-cell diapedesis across
pMBMEC monolayers. To this end, we crossed the PECAM-
1−/− C57BL/6 mice with VE-CadGFP knock-in mice expressing
a VE-cadherin-GFP fusion transcript from the endogenous VE-
cadherin locus, leading to fluorescent labeling of the endothelial
adherens junctions caused by EGFP fused to the VE-cadherin
protein (55). Usage of in vitro cultured pMBMECs isolated from
VE-CadGFP reporter mice, which reportedly do not differ from
WT mice e.g., with regard to barrier resistance (12), allows for
the visualization of endothelial cell-cell junctions during live
cell imaging under physiological flow conditions (Figure 3B)
(12, 63). This allowed us to define the cellular pathway of T-cell
diapedesis across the pMBMEC monolayers as paracellular,
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FIGURE 4 | PECAM-1−/− pMBMECs exhibit impaired barrier properties. (A) Transendothelial electrical resistance (TEER) of pMBMECs grown on filter inserts was
measured by impedance spectroscopy using the cellZscope® (nanoAnalytics) starting 2 days after cell isolation over a period of 5 days in hourly intervals. Solid lines
(black, WT; gray, PECAM-1−/−) represent mean values and shaded areas represent SEM calculated from 6 filter inserts with WT pMBMECs and 5 filter inserts with
PECAM-1−/− pMBMECs, respectively. One representative experiment out of three is shown. (B) Relative TEER of WT and PECAM-1−/− pMBMECs was calculated
from maximal TEER of each filter insert with WT set to 1.0. Graph combines three independent experiments (WT, 23 filter inserts; PECAM-1−/−, 22 filter inserts). Dots
represent individual data points; error bar ± SD. Reported statistics result from unpaired, two-tailed Student’s t-test. Test statistics: p = 0.042, t(43) = 2.096, d =
0.639. (C) Exemplary TEER curves for PBS- and IL-1β-treated WT and PECAM-1−/− pMBMEC monolayers are shown. Dashed lines, PBS-treated filter inserts; solid
lines, IL-1β-treated filter inserts; dotted vertical lines, 16 h time window of stimulation. (D) Relative drop of TEER indicating the decrease of electrical resistance 16 h
after stimulation (final concentration of 20 ng/ml IL-1β per insert) normalized to genotype-matched PBS-treated filter inserts. Dots represent individual data points;
error bar ± SD. Reported statistics result from unpaired, two-tailed Student’s t-test. Test statistics: p = 0.714, t(17) = 0.373, d = 0.181. (E,F) Relative permeability
coefficient of the two different sized fluorescent tracers Lucifer yellow (457 Da) (E) and Alexa-Fluor-680-conjugated 3 kDa dextran (F) across WT and PECAM-1−/−
pMBMEC monolayers normalized to the mean WT value. Data are derived from four independent experiments (WT, 12 filter inserts; PECAM-1−/−, 11 to 12 filter
inserts). Dots represent individual data points; error bar ± SD. Reported statistics result from one-way ANOVAs with Sidak’s multiple comparisons test. Test statistics:
(E) F (3, 43) = 6.382, p = 0.0011, η2 = 0.308; (F) F (3, 43) = 9.375, p < 0.0001, η2 = 0.395; *p < 0.05; ***p < 0.001; ns, not significant.
when we observed a transient interruption of the junctional
GFP signal (Figure 6A), while those diapedesis events leaving
the junctional GFP signal intact were classified as transcellular
diapedesis (Figure 6B).
In accordance with our previous findings (12),
encephalitogenic T cells crossed the IL-1β-stimulated
pMBMEC monolayers equally via the paracellular
(51%) and the transcellular (49%) pathway (Figure 6C,
Supplementary Figure 2). Unexpectedly, lack of PECAM-1
further increased transcellular T-cell diapedesis across the
pMBMEC monolayers to 67%, while only 33% of the T cells
crossed PECAM-1−/− VE-CadGFP pMBMEC monolayers via
the paracellular route. Thus, lack of endothelial PECAM-1
favors transcellular over paracellular T-cell diapedesis across
pMBMEC monolayers.
Lack of PECAM-1 Does Not Affect
Expression of ICAM-1 on pMBMECs
We have previously shown that cell surface levels of endothelial
ICAM-1 direct T cells to transcellular vs. paracellular routes
of diapedesis across pMBMECs (12). While high levels of
endothelial ICAM-1 promoted transcellular T-cell diapedesis,
lower ICAM-1 levels favored paracellular T-cell diapedesis
across pMBMEC monolayers under physiological flow (12).
To exclude that the increased transcellular T-cell diapedesis
across PECAM-1−/− pMBMECs was solely due to an inherently
altered endothelial ICAM-1 expression onWT vs. PECAM-1−/−
pMBMECs, we compared ICAM-1 expression levels in WT
and PECAM-1−/− pMBMECs. Western blot analysis of protein
lysates from unstimulated or IL-1β-treated WT and PECAM-
1−/− pMBMECs (Figures 7A,B; Supplementary Figure 3)
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FIGURE 5 | Lack of endothelial PECAM-1 does not affect T-cell arrest or post-arrest T-cell crawling and diapedesis. Confluent WT and PECAM-1−/− pMBMEC
monolayers were stimulated with IL-1β (20 ng/ml) for 16–24 h prior to live cell imaging. Activated encephalitogenic CD4+ T cells were allowed to arrest on pMBMECs
at low flow (0. 1 dyn/cm2). After 5min, the flow was increased to 1.5 dyn/cm2. For time-lapse videos, pictures were taken every 5 s for a total of 20min. (A) The
number of arrested T cells after increasing the flow rate (frame 60). (B) The behavior of each arrested T cell was determined for the subsequent 15min (frame 60 to
240) and assigned to one of the following categories: detachment, probing behavior, continuous crawling, diapedesis. (C) For all T cells eventually starting to crawl,
the time span between initial arrest to the pMBMECs and the first frame of crawling was determined. (D–F) Each T cell crawling on the activated endothelial
monolayer was tracked and the crawling speed (D), accumulated crawling distance (E), and Euclidian crawling distance (F) were calculated. (G) For all crawling T
cells eventually starting to transmigrate, the time span between halt of movement and start of diapedesis was calculated. (H) For all T cells that finished diapedesis,
the duration of diapedesis was calculated. (I) T cells, which eventually started to transmigrate, were classified according to their prior behavior: crawling or stationary.
Data are derived from 9 videos per pMBMEC genotype performed in three independent experiments. Error bar, ± SD; FOV, field of view; ns, not significant. Reported
statistics result from unpaired, two-tailed Student’s t-tests. Test statistics for (C): p = 0.0488, t(16) = 2.132 (d = 1.066); *p < 0.05; ns, not significant.
showed comparable levels of ICAM-1 protein in WT and
PECAM-1−/− pMBMECs under both conditions (Figure 7A).
Quantification of Western blot signals showed that ICAM-1
expression did not significantly differ between IL-1β-treated WT
and PECAM-1−/− pMBMECs, although ICAM-1 signals varied
to a greater extent in PECAM-1-deficient pMBMEC samples
(Figure 7B). To study cell surface expression of endothelial
ICAM-1 we performed immunofluorescence stainings. We
found that ICAM-1 cell surface expression was not uniform
but rather varied between individual pMBMECs. However, the
ICAM-1 staining pattern was indistinguishable between WT and
PECAM-1−/− pMBMEC monolayers (Figure 7C).
Thus, lack of PECAM-1 did not impact on ICAM-1 protein
levels and its cell surface distribution on pMBMECs. Therefore,
increased transcellular T-cell diapedesis across PECAM-1−/−
pMBMECs is not due to increased expression of ICAM-1.
DISCUSSION
The present analysis of pre-existing microarray data on MS
brain lesions (39, 40) highlighted a profound upregulation
of PECAM-1 transcripts in initial white matter as well as
active cortical gray matter MS lesions. So far, small-scale gene
association studies (64–66) as well as genome-wide association
studies (67–69) have not detected any PECAM-1 gene variants
affecting MS susceptibility. However, its strategic localization at
BBB interendothelial junctions as well as immunohistochemical
findings and blood analyses (33–36, 70) suggest a possible
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FIGURE 6 | Lack of endothelial PECAM-1 favors transcellular over paracellular
diapedesis of encephalitogenic CD4+ T cells across pMBMEC monolayers
under physiological flow. Confluent WT and PECAM-1−/− VE-CadGFP
pMBMEC monolayers were stimulated with IL-1β (20 ng/ml) for 16–24 h prior
to live cell imaging. Activated encephalitogenic CD4+ T cells were allowed to
arrest on pMBMECs at low flow (0. 1 dyn/cm2). After 5min, the flow was
increased to 1.5 dyn/cm2. For time-lapse videos, pictures were taken every
30 s for a total of 30min. For each diapedesis event, the transmigration route
was determined as follows: An opening of GFP-expressing endothelial
junctions was judged as paracellular diapedesis, while a sustained junctional
integrity was indicative of transcellular diapedesis. (A,B) Representative
pictures of paracellular (A) and transcellular (B) diapedesis taken before and
during T-cell diapedesis. Dashed line, site of transmigration; scale bar, 10µm;
DIC, differential interference contrast. (C) In total, 144 and 140T cells, which
completely transmigrated through WT and PECAM-1−/− endothelial
monolayers, respectively, recorded in 68 videos (WT, 34 videos; PECAM-1−/−,
34 videos) were analyzed. Reported statistics of categorical data result from
Pearson’s qui-square test. Test statistics: p = 0.0016, χ2(1) = 9.991, odds
ratio = 2.160; **p < 0.01. In order to provide an estimate for data variability, a
video-wise representation is provided in Supplementary Figure 2.
role for PECAM-1 in MS pathogenesis, including immune cell
trafficking or regulation of BBB integrity. Here, we could show
that in comparison to human control brain tissue, transcript
and protein levels of PECAM-1 were upregulated in initial
(pre-phagocytic) white matter as well as active cortical gray
matter MS lesions. Until now, antibody labeling of post mortem
MS and control tissue has solely shown that the constitutive
expression of PECAM-1 in blood vessels is maintained during
disease (70). However, differential PECAM-1 expression in
endothelial cells has not specifically been addressed so far;
only perivascular and parenchymal macrophages in active
demyelinating lesions have been positively stained for PECAM-
1. Western blot quantification of normal appearing white matter,
distinct white matter lesions, and normal appearing gray matter
in comparison to white and gray matter from healthy control
subjects have not yielded any significant differences in PECAM-
1 levels (70). However, distinctions between endothelial- and
leukocyte-derived PECAM-1 were not possible within protein
lysates. Here, we used archival FFPE material obtained from
acute and progressive MS cases, of which especially the former
present with a high load of inflammation enabling us to examine
prominent molecular changes, which would stay undetected if
less active disease conditions were used for initial screening. In
active white matter lesions from our selected MS brain samples,
we detected faint PECAM-1 reactivity on infiltrating immune
cells. Endothelial PECAM-1 labeling was quite attenuated
compared to initial (pre-phagocytic) white matter lesions, for
which the by far strongest protein expression as well as a
multiple-fold upregulation of mRNA transcripts was found.
Initial (pre-phagocytic) lesions are characterized by commencing
disintegration of myelin and microglia activation as well as tissue
edema accompanied by a loss of tissue structure and mild axonal
injury (45, 46). However, infiltrating lymphocytes or phagocytes
are sparse in these lesions. Thus, the increase of PECAM-1 gene
expression in initial (pre-phagocytic) lesions can be attributed
to an endothelial origin. It was further suggested that PECAM-
1 expression in MS might represent a protective mechanism
(70). At least in in vitro experiments it was shown that IFN-
β, a routinely used disease-modifying drug in MS therapy,
significantly increased endothelial PECAM-1 expression (38).
PECAM-1 is a transmembrane protein with six extracellular
Ig-like domains (16), which facilitate homophilic (71–73) and
heterophilic interactions (74–78). It is expressed in endothelial
cell-cell junctions of the vasculature (17) as well as on platelets,
neutrophils, monocytes and selected lymphocyte subsets (18–
20). Initially, it has been reported that PECAM-1 plays an
indispensable role in the transendothelial migration of myeloid
cells (21, 79–81). For instance, the transmigration of neutrophils
and monocytes through human umbilical vein endothelial cell
(HUVEC) monolayers was massively reduced by anti-PECAM-
1-antibodies and recombinant PECAM-1 protein (21). In this
context, PECAM-1 functions upstream of CD99 and prevents
myeloid cells from entering endothelial junctions (21). In vivo
live cell imaging studies showed that PECAM-1 is neither
involved in leukocyte rolling nor in their subsequent arrest on
the inflamed endothelium, but rather in the subsequent steps
of crossing the vascular wall. In PECAM-1−/− C57BL/6 mice,
which do not show alterations in vascular development, blood
cell counts, and peripheral organmorphology in naïve conditions
(54), leukocytes can still cross the inflamed endothelium in
the absence of PECAM-1, but are subsequently trapped at the
level of the perivascular basement membrane and are thus
inhibited in their migration capacity into the extravascular
tissue (54, 82, 83). Other mouse strains such as FVB/n, SJL
or the outbred strain Swiss Webster show a more pronounced
phenotype in the functional absence of PECAM-1, with clearly
reduced leukocyte extravasation under inflammatory conditions
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FIGURE 7 | Lack of endothelial PECAM-1 does not affect expression levels of ICAM-1 on pMBMECs. (A) WT and PECAM-1−/− pMBMEC monolayers were treated
for 16 h either with IL-1β (20 ng/ml) or left unstimulated. Western blots of cell lysates were incubated with anti-ICAM-1 rabbit serum and rabbit anti-GAPDH antibody.
One representative experiment out of 4 is shown. (B) Quantified ICAM-1 signals were normalized to the reference protein GAPDH. For each experiment, normalized
signals were further related to the unstimulated WT sample. Each individual data point is shown and shapes correlate to the respective independent experiments
(n = 4). Reported statistics result from unpaired, two-tailed Student’s t-test. Test statistics: p = 0.348, t(6) = 1.018, d = 0.831. Error bar, ± SD; ns, not significant.
(C) Untreated and IL-1β-stimulated VE-CadGFP endothelial monolayers stained for ICAM-1 expression (rat hybridoma supernatant 25ZC7). Blue, cell nuclei stained
with DAPI; Scale bar, 60µm.
(23, 84). Interestingly, in the latter mouse strains, functional
or genetic PECAM-1 deficiency was found to arrest leukocytes
at the endothelial junctions before diapedesis started (23, 84).
These observations underscore that there are still additional
components in the diapedesis machinery to be discovered,
which are associated with the role of PECAM-1 in leukocyte
diapedesis. Indeed, a study has already identified a locus on
murine chromosome 2 strongly associated with inflammatory
responses in the absence of PECAM-1 (85). Additional puzzling
observations come from immune cell-mediated disease models
such as experimental autoimmune encephalomyelitis (EAE)
(24), collagen-induced arthritis (86, 87), or atherosclerosis in
low density lipoprotein receptor (LDLR)- or apolipoprotein E
(ApoE)-deficient mice (88, 89), in which absence of PECAM-1
was found to lead to aggravated disease severity.
The majority of studies investigating the role of PECAM-1 in
leukocyte diapedesis have focused onmonocytes and neutrophils,
while the role of endothelial PECAM-1 in T-cell trafficking has
rarely been taken into account. Furthermore, there are very few
studies addressing the role of PECAM-1 in leukocyte trafficking
across the BBB. In fact, one study found the transmigration
rate of T cells to be significantly increased across PECAM-
1-deficient immortalized mouse brain endothelial cells (24).
As endothelial cell lines usually do not possess true BBB-like
characteristics, we used in the present study an established in
vitro BBB model, in which the employed pMBMECs maintain
BBB properties (61). This allowed us to investigate the role of
PECAM-1 in the maintenance of BBB characteristics as well as
in T-cell diapedesis. While absence of PECAM-1 did not affect
the overall junctional architecture of pMBMEC monolayers,
already under non-inflammatory conditions, lack of PECAM-1
in pMBMECs was associated with a decreased transendothelial
electrical resistance (TEER) and increased permeability to small
molecular tracers when compared to WT pMBMECmonolayers.
These findings are in line with previous data showing that
siRNA-silencing of PECAM-1 in endothelial cell lines results in
significantly reduced electrical resistances of both human aortic
endothelial cells (HAECs) or immortalized human umbilical vein
endothelial cells (iHUVECs) (90). In the same study, a potential
contribution of PECAM-1 to junctional repair mechanisms was
found. After thrombin-induced endothelial barrier disruption,
a significantly delayed barrier re-establishment in PECAM-1-
silenced endothelial cell lines was reported. Similarly, we have
previously shown that in vitro histamine challenge of PECAM-
1−/− lung endothelial cells leads to a prolonged permeability
for Evans Blue diffusion compared to PECAM-1−/− lung
endothelial cells transfected with wild-type PECAM-1 (24).
Additionally, PECAM-1−/− C57BL/6 mice suffering from EAE
showed increased vascular permeability for Evans Blue compared
when compared to wild-typemice suffering from EAE (24). Here,
we found that while pro-inflammatory IL-1β stimulation further
reduced the TEER of PECAM-1−/− pMBMEC monolayers it
did not further increase the diffusion of small molecular tracers
across PECAM-1−/− pMBMEC monolayers. This may be due to
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the fact that the diffusion barrier for the small molecular tracers
used in the present study across non-stimulated PECAM-1−/−
pMBMEC monolayers was already too high, thus prohibiting
detection of a further permeability increase by the inflammatory
stimulus in the given experimental setting. Taken together, these
observations underscore a role for endothelial PECAM-1 in the
maintenance of BBB integrity.
To investigate the role of PECAM-1 in T-cell diapedesis across
the BBB, we made use of our human in vitro BBB model and
PECAM-1 blocking antibodies, and found that in contrast to
CD99 and ICAM-1, PECAM-1 is not required for human CD4+
T cell diapedesis across the BBB. We next used our mouse in
vitro BBB model and studied the dynamic interaction of in vitro
activated encephalitogenic CD4+ T cells with pMBMECs under
physiological flow conditions by live cell imaging. We found that
PECAM-1 expression in C57BL/6 mice-derived pMBMECs was
dispensable for the arrest and crawling of T cells as well as for the
number of T cells crossing the pMBMEC monolayer. However,
we observed that endothelial PECAM-1 expression influences the
cellular route of T-cell diapedesis. In the absence of endothelial
PECAM-1, encephalitogenic CD4+ T cells preferentially crossed
IL-1β-stimulated pMBMEC monolayers via a transcellular route
instead of the typically preferred paracellular route across wild-
type pMBMECs.
Lately, we have shown that cell surface levels of endothelial
ICAM-1 direct T cells to either transcellular or paracellular
routes of diapedesis (12). While low to intermediate ICAM-1
expression on pMBMECs favored paracellular diapedesis of in
vitro activated CD4+ T cells, high endothelial ICAM-1 surface
levels led to significantly increased transcellular diapedesis. A
similar finding has been described for in vitro diapedesis of
neutrophils across TNF-α-stimulated iHUVECs overexpressing
ICAM-1 (91), where the enhanced surface levels of ICAM-1 on
the endothelial cells promoted the transcellular transmigration
pathway of polymorphonuclear cells. Translocation of ICAM-
1, accompanied by caveolin-1 and F-actin, to the basal plasma
membrane and its recruitment to caveolae has been described
to initiate the formation of transcellular channels (92). Based
on these observations, it could be argued that the described
altered T-cell diapedesis route across PECAM-1−/− pMBMECs
is triggered by a putative compensatory upregulation of ICAM-1
due to PECAM-1 deficiency. However, our Western Blot analysis
revealed no differential expression of endothelial ICAM-1 in the
absence of endothelial PECAM-1 on IL-1β-treated pMBMECs.
Also, high endothelial ICAM-1 surface expression had been
described to reduce crawling distances and crawling speed of
encephalitogenic CD4+ T cells on pMBMECs (12), which was
not observed in the present study.
The cytoplasmic tail of PECAM-1 harbors two
immunoreceptor tyrosine-based inhibitory motifs (ITIMs)
that, upon phosphorylation, act as docking sites for Src
homology 2 (SH2) domain-containing proteins (93–96).
Thereby, PECAM-1 can act as inhibitory or stimulatory signal
transducer in a cell-specific manner (16, 97). Additionally,
PECAM-1 was shown to coordinate the actin cytoskeleton and
to associate with β- and γ-catenins (98, 99). Protein kinase
C-mediated serine/threonine phosphorylation of PECAM-1 was
shown to inhibit its association with γ-catenin, which was then
translocated into the nucleus (99). Furthermore, PECAM-1-
engagement, in the course of leukocyte transmigration, has been
shown to counteract ICAM-1-induced tyrosine phosphorylation
of cortactin and cytoskeletal actin rearrangements (100), thus
putatively prohibiting excessive endothelial activation and
junctional opening (101). BBB junctional molecules provide
guidance cues facilitating a strictly controlled paracellular T-cell
diapedesis across the BBB e.g., to allow CNS immune surveillance
(102). In fact, as we have previously shown, that the majority
of T cells crosses pMBMEC monolayers via the paracellular
pathway when barrier properties are preserved, while breakdown
of junctional integrity in IL-1β-stimulated pMBMECs correlates
with increased T-cell diapedesis via the transcellular pathway
(12). Thus, loss or incorrect localization of junctional molecules
seems to reduce paracellular T-cell diapedesis across the BBB.
The BBB is characterized by unique barrier functions, which
are, amongst others, maintained by limited vesicular activity
(103). The remainder of vesicles comprises caveolin 1-containing
caveolae (104, 105). During multiple sclerosis (MS) and EAE,
the number of caveolae was found to be increased in the CNS
endothelium resulting in clustering of adhesion molecules at the
luminal side of the vasculature (92, 106), which in turn might
facilitate the transcellular route of T cell diapedesis into the
CNS. Indeed, a recent study employing intravital microscopy
in claudin-5 reporter mice showed that during the onset of
EAE, T-cell diapedesis across the BBB mainly occurs via a
caveolae-independent paracellular pathway, while caveolae
regulate transcellular T cell diapedesis across the BBB during
ongoing neuroinflammation (13).
Taken together, our data demonstrate that PECAM-1 is
involved in the regulation of BBB integrity. At the same time,
PECAM-1 is neither required for human T-cell diapedesis across
human BBB-like endothelial cells in vitro nor for murine T-cell
diapedesis across pMBMECs under flow in vitro. The lack of
PECAM-1 on pMBMECs rather directs T-cell diapedesis to the
transcellular route, while in its presence T-cell diapedesis across
stimulated pMBMECs occurs equally on both the transcellular
and the paracellular route. The shift in the preferential T-cell
diapedesis pathway across PECAM-1−/− pMBMECs might be
due to non-antagonized ICAM-1-signaling in PECAM-1−/−
pMBMECs establishing the transcellular pathway via caveolin-
1/F-actin-enriched channels (13). ICAM-1 is significantly
expressed during early lesion formation in MS and EAE (107).
Upregulated vascular PECAM-1 expression in initial (pre-
phagocytic) white matter as well as active cortical gray matter
MS lesions thus might represent a compensatory mechanism
to repair BBB characteristics and to prevent uncontrolled
immune cell infiltration via the transcellular pathway, which
is seemingly facilitated by inflammatory cytokine (e.g., IL-1β)-
mediated ICAM-1 upregulation and ICAM-1 signaling in brain
endothelial cells. This hypothesis is further supported by the
fact that PECAM-1−/− mice exhibit increased numbers of CNS-
infiltrating immune cells in the course of EAE (24). Finally,
while studying the functional absence of PECAM-1 at the BBB
has allowed us to identify its role in maintaining BBB integrity
and in regulating the cellular pathway of T-cell diapedesis across
the BBB, overexpression of PECAM-1 may induce additional
mechanisms that cannot be predicted from studying absence
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of PECAM-1. Furthermore, the role of PECAM-1 in mediating
the CNS entry of additional immune cell subsets contributing
to MS pathogenesis, e.g., CD8+ T cells and B cells remains to
be explored.
AUTHOR CONTRIBUTIONS
IW and ST designed and performed experiments, analyzed
data, and wrote the manuscript. HN designed and performed
experiments and contributed to manuscript writing. UD
managed and maintained the transgenic mouse colonies and
edited the manuscript. WM and FG provided reagents, cells and
advice for the study and edited the manuscript. FS provided
T cells and advice for the study. RL supervised parts of the
study and contributed to manuscript writing. HL designed and
supervised the analysis of human autopsy tissue and contributed
to manuscript writing. BE designed and supervised the in vitro
studies and wrote and edited the manuscript.
FUNDING
This study was supported by the Swiss National Science
Foundation (SNSF grants N◦ 133092 and 170131) and the EU
FP7 funded collaborative project JUSTBRAIN (HEALTH-F2-
2009-241861) and the Bangerter-Rhyner Foundation to BE, the
SNSF funded Sinergia project UnmetMS (CRSII3_154483) to BE
and FS, the Austrian Science Fund (grant N◦ W1205-B09[II]) to
HL, a Du Pré Grant of theMS International Federation to IW and
by an ECTRIMS Postdoctoral Research Exchange Fellowship and
the Uehara Memorial Foundation to HN.
ACKNOWLEDGMENTS
We gratefully acknowledge the expert technical and experimental
support from Claudia Blatti, Mariana Dias, David Jarrossay, Elisa
Kaba, Ulrike Köck, Angela Kury, Daniela Latorre, Marianne
Leißer, Mark Liebi, Albert Witt, and Tobias Zrzavy (list
in alphabetical order). We furthermore express our thanks
to our animal caretakers for state-of-the art experimental
animal husbandry.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.00711/full#supplementary-material
REFERENCES
1. Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med.
(2018) 8:a028936. doi: 10.1101/cshperspect.a028936
2. Tommasin S, Gianni C, De Giglio L, Pantano P. Neuroimaging techniques
to assess inflammation in Multiple Sclerosis. Neuroscience. (2019) 403:4–16.
doi: 10.1016/j.neuroscience.2017.07.055
3. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R,
et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate
in active multiple sclerosis lesions as shown by micromanipulation and
single cell polymerase chain reaction. J Exp Med. (2000) 192:393–404.
doi: 10.1084/jem.192.3.393
4. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka
H, Schmidbauer M, et al. The relation between inflammation and
neurodegeneration in multiple sclerosis brains. Brain. (2009) 132:1175–89.
doi: 10.1093/brain/awp070
5. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L,
Miller DH, et al. A randomized, placebo-controlled trial of natalizumab
for relapsing multiple sclerosis. N Engl J Med. (2006) 354:899–910.
doi: 10.1056/NEJMoa044397
6. Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin
G. Functional morphology of the blood-brain barrier in health and
disease. Acta Neuropathol. (2018) 135:311–36. doi: 10.1007/s00401-
018-1815-1
7. Tietz S, Engelhardt B. Brain barriers: crosstalk between complex tight
junctions and adherens junctions. J Cell Biol. (2015) 209:493–506.
doi: 10.1083/jcb.201412147
8. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code
to breach the blood-brain barriers. Trends Immunol. (2012) 33:579–89.
doi: 10.1016/j.it.2012.07.004
9. Winger RC, Koblinski JE, Kanda T, Ransohoff RM, Muller WA. Rapid
remodeling of tight junctions during paracellular diapedesis in a human
model of the blood-brain barrier. J Immunol. (2014) 193:2427–37.
doi: 10.4049/jimmunol.1400700
10. Carman CV, Sage PT, Sciuto TE, de la Fuente MA, Geha RS, Ochs HD,
et al. Transcellular diapedesis is initiated by invasive podosomes. Immunity.
(2007) 26:784–97. doi: 10.1016/j.immuni.2007.04.015
11. Engelhardt B, Wolburg H. Mini-review: transendothelial migration
of leukocytes: through the front door or around the side of the
house? Eur J Immunol. (2004) 34:2955–63. doi: 10.1002/eji.2004
25327
12. Abadier M, Haghayegh Jahromi N, Cardoso Alves L, Boscacci R, Vestweber
D, Barnum S, et al. Cell surface levels of endothelial ICAM-1 influence
the transcellular or paracellular T-cell diapedesis across the blood-
brain barrier. Eur J Immunol. (2015) 45:1043–58. doi: 10.1002/eji.2014
45125
13. Lutz SE, Smith JR, KimDH,Olson CVL, Ellefsen K, Bates JM, et al. Caveolin1
is required for Th1 cell infiltration, but not tight junction remodeling, at
the blood-brain barrier in autoimmune neuroinflammation. Cell Rep. (2017)
21:2104–17. doi: 10.1016/j.celrep.2017.10.094
14. Newman PJ, Berndt MC, Gorski J, White GC II, Lyman S, Paddock
C, et al. PECAM-1 (CD31) cloning and relation to adhesion molecules
of the immunoglobulin gene superfamily. Science. (1990) 247:1219–22.
doi: 10.1126/science.1690453
15. Simmons DL, Walker C, Power C, Pigott R. Molecular cloning of CD31, a
putative intercellular adhesion molecule closely related to carcinoembryonic
antigen. J Exp Med. (1990) 171:2147–52. doi: 10.1084/jem.171.6.2147
16. Newman PJ, Newman DK. Signal transduction pathways mediated
by PECAM-1: new roles for an old molecule in platelet and vascular
cell biology. Arterioscler Thromb Vasc Biol. (2003) 23:953–64.
doi: 10.1161/01.ATV.0000071347.69358.D9
17. Muller WA, Ratti CM, McDonnell SL, Cohn ZA. A human
endothelial cell-restricted, externally disposed plasmalemmal protein
enriched in intercellular junctions. J Exp Med. (1989) 170:399–414.
doi: 10.1084/jem.170.2.399
18. Stockinger H, Gadd SJ, Eher R, Majdic O, Schreiber W, Kasinrerk W, et al.
Molecular characterization and functional analysis of the leukocyte surface
protein CD31. J Immunol. (1990) 145:3889–97.
19. Ashman LK, Aylett GW. Expression of CD31 epitopes on human
lymphocytes: CD31 monoclonal antibodies differentiate between naive
(CD45RA+) and memory (CD45RA-) CD4-positive T cells. Tissue Antigens.
(1991) 38:208–12. doi: 10.1111/j.1399-0039.1991.tb01899.x
20. Bird IN, Spragg JH, Ager A, Matthews N. Studies of lymphocyte
transendothelial migration: analysis of migrated cell phenotypes with
Frontiers in Immunology | www.frontiersin.org 14 April 2019 | Volume 10 | Article 711
Wimmer et al. PECAM-1 in Neuroinflammation
regard to CD31 (PECAM-1), CD45RA and CD45RO. Immunology.
(1993) 80:553–60.
21. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for
transendothelial migration of leukocytes. J Exp Med. (1993) 178:449–60.
doi: 10.1084/jem.178.2.449
22. Mamdouh Z, Chen X, Pierini LM, Maxfield FR, Muller WA. Targeted
recycling of PECAM from endothelial surface-connected compartments
during diapedesis. Nature. (2003) 421:748–53. doi: 10.1038/nature01300
23. Schenkel AR, Chew TW, Muller WA. Platelet endothelial cell adhesion
molecule deficiency or blockade significantly reduces leukocyte
emigration in a majority of mouse strains. J Immunol. (2004) 173:6403–8.
doi: 10.4049/jimmunol.173.10.6403
24. Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A, Davis S,
et al. Altered vascular permeability and early onset of experimental
autoimmune encephalomyelitis in PECAM-1–deficient mice. J Clin Invest.
(2002) 109:383–92. doi: 10.1172/JCI0213595
25. Biswas P, Canosa S, Schoenfeld D, Schoenfeld J, Li P, Cheas LC, et al. PECAM-
1 affects GSK-3β-mediated β-catenin phosphorylation and degradation. Am
J Pathol. (2006) 169:314–24. doi: 10.2353/ajpath.2006.051112
26. Osawa M, Masuda M, Kusano K, Fujiwara K. Evidence for a role of platelet
endothelial cell adhesion molecule-1 in endothelial cell mechanosignal
transduction: is it a mechanoresponsive molecule? J Cell Biol. (2002)
158:773–85. doi: 10.1083/jcb.200205049
27. Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, Engelhardt B,
et al. A mechanosensory complex that mediates the endothelial cell response
to fluid shear stress. Nature. (2005) 437:426–31. doi: 10.1038/nature03952
28. Collins C, Guilluy C, Welch C, O’Brien ET, Hahn K, Superfine R, et al.
Localized tensional forces on PECAM-1 elicit a global mechanotransduction
response via the integrin-RhoA pathway. Curr Biol. (2012) 22:2087–94.
doi: 10.1016/j.cub.2012.08.051
29. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD,
Robinson CS, Wexler RS, et al. Involvement of endothelial PECAM-1/CD31
in angiogenesis. Am J Pathol. (1997) 151:671–7.
30. Cao G, O’Brien CD, Zhou Z, Sanders SM, Greenbaum JN, Makrigiannakis
A, et al. Involvement of human PECAM-1 in angiogenesis and in vitro
endothelial cell migration. Am J Physiol Cell Physiol. (2002) 282:C1181–90.
doi: 10.1152/ajpcell.00524.2001
31. Chen Z, Tzima E. PECAM-1 is necessary for flow-induced vascular
remodeling. Arterioscler Thromb Vasc Biol. (2009) 29:1067–73.
doi: 10.1161/ATVBAHA.109.186692
32. Privratsky JR, Newman PJ. PECAM-1: regulator of endothelial junctional
integrity. Cell Tissue Res. (2014) 355:607–19. doi: 10.1007/s00441-
013-1779-3
33. Losy J, Niezgoda A, Wender M. Increased serum levels of soluble
PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing
lesions. J Neuroimmunol. (1999) 99:169–72. doi: 10.1016/S0165-5728(99)
00092-2
34. Kuenz B, Lutterotti A, Khalil M, Ehling R, Gneiss C, Deisenhammer
F, et al. Plasma levels of soluble adhesion molecules sPECAM-1, sP-
selectin and sE-selectin are associated with relapsing-remitting disease
course of multiple sclerosis. J Neuroimmunol. (2005) 167:143–9.
doi: 10.1016/j.jneuroim.2005.06.019
35. Minagar A, Jy W, Jimenez JJ, Sheremata WA, Mauro LM, Mao WW, et al.
Elevated plasma endothelial microparticles in multiple sclerosis. Neurology.
(2001) 56:1319–24. doi: 10.1212/WNL.56.10.1319
36. Niezgoda A, Losy J. Pecam-1 expression in patients with relapsing-remitting
multiple sclerosis. Folia Morphol. (2002) 61:143–5.
37. Mitsikostas DD, Goodin DS. Comparing the efficacy of disease-modifying
therapies in multiple sclerosis. Mult Scler Relat Disord. (2017) 18:109–16.
doi: 10.1016/j.msard.2017.08.003
38. Nelissen I, Ronsse I, Van Damme J, Opdenakker G. Regulation of
gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation
and its modulation by interferon-beta. J Leukoc Biol. (2002) 71:89–98.
doi: 10.1189/jlb.71.1.89
39. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, et al.
NADPH oxidase expression in active multiple sclerosis lesions in relation
to oxidative tissue damage and mitochondrial injury. Brain. (2012) 135(Pt
3):886–99. doi: 10.1093/brain/aws012
40. Fischer MT, Wimmer I, Hoftberger R, Gerlach S, Haider L, Zrzavy
T, et al. Disease-specific molecular events in cortical multiple
sclerosis lesions. Brain. (2013) 136(Pt 6):1799–815. doi: 10.1093/
brain/awt110
41. Hametner S, Wimmer I, Haider L, Pfeifenbring S, Bruck W, Lassmann H.
Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol.
(2013) 74:848–61. doi: 10.1002/ana.23974
42. Schuh C, Wimmer I, Hametner S, Haider L, Van Dam AM, Liblau
RS, et al. Oxidative tissue injury in multiple sclerosis is only partly
reflected in experimental disease models. Acta Neuropathol. (2014).
doi: 10.1007/s00401-014-1263-5
43. Licht-Mayer S, Wimmer I, Traffehn S, Metz I, Bruck W, Bauer J, et al. Cell
type-specific Nrf2 expression in multiple sclerosis lesions. Acta Neuropathol.
(2015) 130:263–77. doi: 10.1007/s00401-015-1452-x
44. Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann
H. Loss of ’homeostatic’ microglia and patterns of their activation in
active multiple sclerosis. Brain. (2017) 140:1900–13. doi: 10.1093/brain/
awx113
45. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis:
pathology of the newly forming lesion. Ann Neurol. (2004) 55:458–68.
doi: 10.1002/ana.20016
46. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. Lesion genesis in a subset
of patients with multiple sclerosis: a role for innate immunity? Brain. (2007)
130(Pt 11):2800–15. doi: 10.1093/brain/awm236
47. BruckW, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, et al.
Monocyte/macrophage differentiation in early multiple sclerosis lesions.
Ann Neurol. (1995) 38:788–96. doi: 10.1002/ana.410380514
48. Lassmann H. Review: the architecture of inflammatory demyelinating
lesions: implications for studies on pathogenesis. Neuropathol Appl
Neurobiol. (2011) 37:698–710. doi: 10.1111/j.1365-2990.2011.01189.x
49. Bauer J, Lassmann H. Neuropathological techniques to investigate central
nervous system sections in multiple sclerosis. Methods Mol Biol. (2016)
1304:211–29. doi: 10.1007/7651_2014_151
50. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, et al.
Rapid and coordinated switch in chemokine receptor expression during
dendritic cell maturation. Eur J Immunol. (1998) 28:2760–9.
51. Engen SA, Valen Rukke H, Becattini S, Jarrossay D, Blix IJ, Petersen FC,
et al. The oral commensal Streptococcus mitis shows a mixed memory Th cell
signature that is similar to and cross-reactive with Streptococcus pneumoniae.
PLoS ONE. (2014) 9:e104306. doi: 10.1371/journal.pone.0104306
52. Cecchelli R, Aday S, Sevin E, Almeida C, Culot M, Dehouck L,
et al. A stable and reproducible human blood-brain barrier model
derived from hematopoietic stem cells. PLoS ONE. (2014) 9:e99733.
doi: 10.1371/journal.pone.0099733
53. Lyck R, Lecuyer MA, Abadier M,Wyss CB, Matti C, Rosito M, et al. ALCAM
(CD166) is involved in extravasation of monocytes rather than T cells across
the blood-brain barrier. J Cereb Blood Flow Metab. (2017) 37:2894–909.
doi: 10.1177/0271678X16678639
54. Duncan GS, Andrew DP, Takimoto H, Kaufman SA, Yoshida H,
Spellberg J, et al. Genetic evidence for functional redundancy of
Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient
mice reveal PECAM-1-dependent and PECAM-1-independent functions. J
Immunol. (1999) 162:3022–30.
55. Winderlich M, Keller L, Cagna G, Broermann A, Kamenyeva O, Kiefer F,
et al. VE-PTP controls blood vessel development by balancing Tie-2 activity.
J Cell Biol. (2009) 185:657–71. doi: 10.1083/jcb.200811159
56. Coisne C, Dehouck L, Faveeuw C, Delplace Y, Miller F, Landry C, et al.
Mouse syngenic in vitro blood-brain barrier model: a new tool to examine
inflammatory events in cerebral endothelium. Lab Invest. (2005) 85:734–46.
doi: 10.1038/labinvest.3700281
57. Lyck R, Ruderisch N, Moll AG, Steiner O, Cohen CD, Engelhardt B, et al.
Culture-induced changes in blood-brain barrier transcriptome: implications
for amino-acid transporters in vivo. J Cereb Blood Flow Metab. (2009)
29:1491–502. doi: 10.1038/jcbfm.2009.72
58. Engelhardt B, Laschinger M, Schulz M, Samulowitz U, Vestweber D, Hoch
G. The development of experimental autoimmune encephalomyelitis in the
mouse requires alpha4-integrin but not alpha4beta7-integrin. J Clin Invest.
(1998) 102:2096–105. doi: 10.1172/JCI4271
Frontiers in Immunology | www.frontiersin.org 15 April 2019 | Volume 10 | Article 711
Wimmer et al. PECAM-1 in Neuroinflammation
59. Coisne C, Lyck R, Engelhardt B. Live cell imaging techniques to study T cell
trafficking across the blood-brain barrier in vitro and in vivo. Fluids Barriers
CNS. (2013) 10:7. doi: 10.1186/2045-8118-10-7
60. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno
M, et al. Pathogen-induced human TH17 cells produce IFN-gamma
or IL-10 and are regulated by IL-1beta. Nature. (2012) 484:514–8.
doi: 10.1038/nature10957
61. Steiner O, Coisne C, Engelhardt B, Lyck R. Comparison of immortalized
bEnd5 and primary mouse brain microvascular endothelial cells as in vitro
blood-brain barrier models for the study of T cell extravasation. J Cereb Blood
Flow Metab. (2011) 31:315–27. doi: 10.1038/jcbfm.2010.96
62. Wessel F, Winderlich M, Holm M, Frye M, Rivera-Galdos R, Vockel M,
et al. Leukocyte extravasation and vascular permeability are each controlled
in vivo by different tyrosine residues of VE-cadherin. Nat Immunol. (2014)
15:223–30. doi: 10.1038/ni.2824
63. Rudolph H, Klopstein A, Gruber I, Blatti C, Lyck R, Engelhardt B. Postarrest
stalling rather than crawling favors CD8(+) over CD4(+) T-cell migration
across the blood-brain barrier under flow in vitro. Eur J Immunol. (2016)
46:2187–203. doi: 10.1002/eji.201546251
64. Nelissen I, Fiten P, Vandenbroeck K, Hillert J, Olsson T, Marrosu MG,
et al. PECAM1, MPO and PRKAR1A at chromosome 17q21-q24 and
susceptibility for multiple sclerosis in Sweden and Sardinia. J Neuroimmunol.
(2000) 108:153–9. doi: 10.1016/S0165-5728(00)00293-9
65. Sciacca FL, Ferri C, D’Alfonso S, Bolognesi E, Martinelli Boneschi F,
Cuzzilla B, et al. Association study of a new polymorphism in the
PECAM-1 gene in multiple sclerosis. J Neuroimmunol. (2000) 104:174–8.
doi: 10.1016/S0165-5728(99)00274-X
66. Nelissen I, Dubois B, Goris A, Ronsse I, Carton H, Opdenakker G. Gelatinase
B, PECAM-1 and MCP-3 gene polymorphisms in Belgian multiple sclerosis.
J Neurol Sci. (2002) 200:43–8. doi: 10.1016/S0022-510X(02)00129-6
67. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA,
Moutsianas L, et al. Genetic risk and a primary role for cell-mediated
immune mechanisms in multiple sclerosis. Nature. (2011) 476:214–9.
doi: 10.1038/nature10251
68. Patsopoulos NA, Barcellos LF, Hintzen RQ, Schaefer C, van Duijn CM,
Noble JA, et al. Fine-mapping the genetic association of the major
histocompatibility complex in multiple sclerosis: HLA and non-HLA effects.
PLoS Genet. (2013) 9:e1003926. doi: 10.1371/journal.pgen.1003926
69. Patsopoulos N, Baranzini SE, Santaniello A, Shoostari P, Cotsapas C, Wong
G, et al. The multiple sclerosis genomic map: role of peripheral immune cells
and resident microglia in susceptibility (2017). bioRxiv. doi: 10.1101/143933
70. Nelissen I, Gveric D, van Noort JM, Cuzner ML, Opdenakker G.
PECAM-1 and gelatinase B coexist in vascular cuffs of multiple
sclerosis lesions. Neuropathol Appl Neurobiol. (2006) 32:15–22.
doi: 10.1111/j.1365-2990.2006.00677.x
71. Sun J, Williams J, Yan HC, Amin KM, Albelda SM, DeLisser HM. Platelet
endothelial cell adhesion molecule-1 (PECAM-1) homophilic adhesion is
mediated by immunoglobulin-like domains 1 and 2 and depends on the
cytoplasmic domain and the level of surface expression. J Biol Chem. (1996)
271:18561–70. doi: 10.1074/jbc.271.31.18561
72. Sun QH, DeLisser HM, Zukowski MM, Paddock C, Albelda SM, Newman
PJ. Individually distinct Ig homology domains in PECAM-1 regulate
homophilic binding and modulate receptor affinity. J Biol Chem. (1996)
271:11090–8. doi: 10.1074/jbc.271.19.11090
73. Newton JP, Buckley CD, Jones EY, Simmons DL. Residues on both
faces of the first immunoglobulin fold contribute to homophilic
binding sites of PECAM-1/CD31. J Biol Chem. (1997) 272:20555–63.
doi: 10.1074/jbc.272.33.20555
74. DeLisser HM, Yan HC, Newman PJ, Muller WA, Buck CA, Albelda
SM. Platelet/endothelial cell adhesion molecule-1 (CD31)-mediated cellular
aggregation involves cell surface glycosaminoglycans. J Biol Chem.
(1993) 268:16037–46.
75. Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D, et al.
CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in
adhesion of leukocytes to endothelium. J Cell Biol. (1995) 130:451–60.
doi: 10.1083/jcb.130.2.451
76. Buckley CD, Doyonnas R, Newton JP, Blystone SD, Brown EJ, Watt SM, et al.
Identification of alpha v beta 3 as a heterotypic ligand for CD31/PECAM-1.
J Cell Sci. (1996) 109(Pt 2):437–45.
77. Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, et al.
Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig
superfamily member. J Immunol. (1998) 160:395–402.
78. Sachs UJ, Andrei-Selmer CL, Maniar A, Weiss T, Paddock C, Orlova VV,
et al. The neutrophil-specific antigen CD177 is a counter-receptor for platelet
endothelial cell adhesionmolecule-1 (CD31). J Biol Chem. (2007) 282:23603–
12. doi: 10.1074/jbc.M701120200
79. Vaporciyan AA, DeLisser HM, Yan HC, Mendiguren II, Thom SR,
Jones ML, et al. Involvement of platelet-endothelial cell adhesion
molecule-1 in neutrophil recruitment in vivo. Science. (1993) 262:1580–2.
doi: 10.1126/science.8248808
80. Bogen S, Pak J, Garifallou M, Deng X, Muller WA. Monoclonal antibody to
murine PECAM-1 (CD31) blocks acute inflammation in vivo. J Exp Med.
(1994) 179:1059–64. doi: 10.1084/jem.179.3.1059
81. Liao F, Huynh HK, Eiroa A, Greene T, Polizzi E, Muller WA. Migration
of monocytes across endothelium and passage through extracellular matrix
involve separate molecular domains of PECAM-1. J Exp Med. (1995)
182:1337–43. doi: 10.1084/jem.182.5.1337
82. Wakelin MW, Sanz MJ, Dewar A, Albelda SM, Larkin SW, Boughton-Smith
N, et al. An anti-platelet-endothelial cell adhesion molecule-1 antibody
inhibits leukocyte extravasation from mesenteric microvessels in vivo by
blocking the passage through the basement membrane. J Exp Med. (1996)
184:229–39. doi: 10.1084/jem.184.1.229
83. Thompson RD, Noble KE, Larbi KY, Dewar A, Duncan GS, Mak TW,
et al. Platelet-endothelial cell adhesion molecule-1 (PECAM-1)-deficient
mice demonstrate a transient and cytokine-specific role for PECAM-1 in
leukocyte migration through the perivascular basement membrane. Blood.
(2001) 97:1854–60. doi: 10.1182/blood.V97.6.1854
84. Sullivan DP, Watson RL, Muller WA. 4D intravital microscopy uncovers
critical strain differences for the roles of PECAM and CD99 in
leukocyte diapedesis. Am J Physiol Heart Circ Physiol. (2016) 311:H621–32.
doi: 10.1152/ajpheart.00289.2016
85. Seidman MA, Chew TW, Schenkel AR, Muller WA. PECAM-independent
thioglycollate peritonitis is associated with a locus on murine chromosome
2. PLoS ONE. (2009) 4:e4316. doi: 10.1371/journal.pone.0004316
86. Tada Y, Koarada S, Morito F, Ushiyama O, Haruta Y, Kanegae F, et al.
Acceleration of the onset of collagen-induced arthritis by a deficiency
of platelet endothelial cell adhesion molecule 1. Arthritis Rheum. (2003)
48:3280–90. doi: 10.1002/art.11268
87. Wong MX, Hayball JD, Hogarth PM, Jackson DE. The inhibitory co-
receptor, PECAM-1 provides a protective effect in suppression of collagen-
induced arthritis. J Clin Immunol. (2005) 25:19–28. doi: 10.1007/s10875-005-
0354-7
88. Groyer E, Nicoletti A, Ait-Oufella H, Khallou-Laschet J, Varthaman A,
Gaston AT, et al. Atheroprotective effect of CD31 receptor globulin through
enrichment of circulating regulatory T-cells. J Am Coll Cardiol. (2007)
50:344–50. doi: 10.1016/j.jacc.2007.04.040
89. Goel R, Schrank BR, Arora S, Boylan B, Fleming B, Miura H, et al.
Site-specific effects of PECAM-1 on atherosclerosis in LDL receptor-
deficient mice. Arterioscler Thromb Vasc Biol. (2008) 28:1996–2002.
doi: 10.1161/ATVBAHA.108.172270
90. Privratsky JR, Paddock CM, Florey O, Newman DK, Muller WA, Newman
PJ. Relative contribution of PECAM-1 adhesion and signaling to the
maintenance of vascular integrity. J Cell Sci. (2011) 124(Pt 9):1477–85.
doi: 10.1242/jcs.082271
91. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW.
ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-
alpha-activated vascular endothelium under flow. Blood. (2005) 106:584–92.
doi: 10.1182/blood-2004-12-4942
92. Millan J, Hewlett L, Glyn M, Toomre D, Clark P, Ridley AJ. Lymphocyte
transcellular migration occurs through recruitment of endothelial ICAM-
1 to caveola- and F-actin-rich domains. Nat Cell Biol. (2006) 8:113–23.
doi: 10.1038/ncb1356
Frontiers in Immunology | www.frontiersin.org 16 April 2019 | Volume 10 | Article 711
Wimmer et al. PECAM-1 in Neuroinflammation
93. Jackson DE, Ward CM, Wang R, Newman PJ. The protein-tyrosine
phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-
1 (PECAM-1) and forms a distinct signaling complex during platelet
aggregation. Evidence for a mechanistic link between PECAM-1- and
integrin-mediated cellular signaling. J Biol Chem. (1997) 272:6986–93.
doi: 10.1074/jbc.272.11.6986
94. Masuda M, Osawa M, Shigematsu H, Harada N, Fujiwara K. Platelet
endothelial cell adhesion molecule-1 is a major SH-PTP2 binding
protein in vascular endothelial cells. FEBS Lett. (1997) 408:331–6.
doi: 10.1016/S0014-5793(97)00457-2
95. Sagawa K, Kimura T, Swieter M, Siraganian RP. The protein-tyrosine
phosphatase SHP-2 associates with tyrosine-phosphorylated adhesion
molecule PECAM-1 (CD31). J Biol Chem. (1997) 272:31086–91.
doi: 10.1074/jbc.272.49.31086
96. Hua CT, Gamble JR, Vadas MA, Jackson DE. Recruitment and activation
of SHP-1 protein-tyrosine phosphatase by human platelet endothelial
cell adhesion molecule-1 (PECAM-1). Identification of immunoreceptor
tyrosine-based inhibitory motif-like binding motifs and substrates. J Biol
Chem. (1998) 273:28332–40. doi: 10.1074/jbc.273.43.28332
97. Newman DK, Hamilton C, Newman PJ. Inhibition of antigen-receptor
signaling by platelet endothelial cell adhesion molecule-1 (CD31)
requires functional ITIMs, SHP-2, and p56(lck). Blood. (2001) 97:2351–7.
doi: 10.1182/blood.V97.8.2351
98. Matsumura T, Wolff K, Petzelbauer P. Endothelial cell tube formation
depends on cadherin 5 and CD31 interactions with filamentous actin. J
Immunol. (1997) 158:3408–16.
99. Ilan N, Cheung L, Pinter E, Madri JA. Platelet-endothelial cell adhesion
molecule-1 (CD31), a scaffolding molecule for selected catenin
family members whose binding is mediated by different tyrosine and
serine/threonine phosphorylation. J Biol Chem. (2000) 275:21435–43.
doi: 10.1074/jbc.M001857200
100. Couty JP, Rampon C, Leveque M, Laran-Chich MP, Bourdoulous
S, Greenwood J, et al. PECAM-1 engagement counteracts ICAM-1-
induced signaling in brain vascular endothelial cells. J Neurochem. (2007)
103:793–801. doi: 10.1111/j.1471-4159.2007.04782.x
101. Privratsky JR, Newman DK, Newman PJ. PECAM-1: conflicts of
interest in inflammation. Life Sci. (2010) 87:69–82. doi: 10.1016/j.lfs.2010.
06.001
102. Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune
privilege of the CNS. Nat Immunol. (2017) 18:123–31. doi: 10.1038/ni.3666
103. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid
barriers: function and dysfunction. Semin Immunopathol. (2009) 31:497–
511. doi: 10.1007/s00281-009-0177-0
104. Nag S. Ultracytochemical studies of the compromised blood-brain barrier.
Methods Mol Med. (2003) 89:145–60. doi: 10.1385/1-59259-419-0:145
105. Kovtun O, Tillu VA, Ariotti N, Parton RG, Collins BM. Cavin family
proteins and the assembly of caveolae. J Cell Sci. (2015) 128:1269–78.
doi: 10.1242/jcs.167866
106. Carman CV, Martinelli R. T Lymphocyte-Endothelial Interactions: emerging
understanding of trafficking and antigen-specific immunity. Front Immunol.
(2015) 6:603. doi: 10.3389/fimmu.2015.00603
107. Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1
(ICAM-1) in cellular immune reactions in the human central nervous
system. Am J Pathol. (1990) 136:1309–16.
Conflict of Interest Statement:HL received honoraria for lectures from Novartis,
Biogen, and Sanofi Aventis. Moreover, he is a member of advisory boards at Roche
and Medday. BE receives research support from Biogen.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Wimmer, Tietz, Nishihara, Deutsch, Sallusto, Gosselet, Lyck,
Muller, Lassmann and Engelhardt. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 17 April 2019 | Volume 10 | Article 711
